Skip to content

Recovery

BPC-157 Arginate

Also called PDA, Pentadeca Arginate

InjectableEvidence DEvery day
Half-life
4hours
Typical vial
5 / 10mg
Research amounts
200–500mcg

per administration

Common schedule
Every day
From community reports

The amounts going around come from sellers and forums, not from any study.

Work out your draw

These numbers are a starting point — change any of them.

3 mL cartridge · 300 units loaded12units dialled
Concentration
1.67mg/mL
Volume per draw
0.12mL
Units to dial
12
Doses per cartridge
25

Vial label

Copy this into your label printer.

Published research contexts for BPC-157 Arginate describe 200500 mcg per administration. Descriptive only, not a recommendation.

No pharmacokinetic data of its own; carried over from BPC-157, which is poorly characterized.

An arginate salt form of BPC-157, marketed as pentadeca arginate. No study covers the salt separately from BPC-157, whose own evidence is preclinical and community-derived, so its figures are carried over here and no schedule table is shown.

Modelled level — every day

1× is the peak after a single dose.

Steady-state peak
1.02× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
20hours

About five half-lives

Administrations
7/ week

Where these numbers come from

  • BPC-157 preclinical literatureNo literature covers the arginate salt on its own; see the BPC-157 page for the parent's preclinical sources.

Next steps

Others in recovery